- Conditions
- Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
- Interventions
- Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
- Procedure · Drug · Combination Product
- Lead sponsor
- Gary Van Guilder
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Gunnison, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–35
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dry Eye Disease
- Interventions
- Xalatan, Travatan Z
- Drug
- Lead sponsor
- Ophthalmic Consultants of Long Island
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more
- Conditions
- Female Sexual Arousal Disorder
- Interventions
- Sildenafil 100 mg, Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Asymptomatic Condition
- Interventions
- Graston Instrument assisted Soft tissue Mobilization
- Procedure
- Lead sponsor
- Florida Gulf Coast University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- KPI-121, Placebo
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 11
- States / cities
- Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more
- Conditions
- Lactation Suppressed
- Interventions
- Cabergoline 1 MG, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Ocular Hyperemia
- Interventions
- Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 918 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Cognition, Oxidative Stress, Gut Microbiota, Overweight, Inflammation, Microvascular Function, Body Composition
- Interventions
- Wild Blueberry, Placebo
- Dietary Supplement
- Lead sponsor
- Georgia State University
- Other
- Eligibility
- 20 Years to 65 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hyperemia
- Interventions
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee